Literature DB >> 9484503

N-[trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl]-L-alanyl-D-glutamic acid: a novel immunologically active carbocyclic muramyl dipeptide analogue.

D Kikelj1, S Pecar, V Kotnik, A Stalc, B Wraber-Herzog, S Simcic, A Ihan, L Klamfer, L Povsic, R Grahek, E Suhadolc, M Hocevar, H Hönig, R Rogi-Kohlenprath.   

Abstract

A novel non-pyrogenic carbocyclic muramyl dipeptide (MDP) analogue, N-¿trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl¿-L-alanyl-D-glutamic acid, was obtained by replacement of the N-acetylmuramic acid part and the D-isoglutamine residue of the MDP molecule by a trans-2-[[2'-(acetylamino)cyclohexyl]oxy]acetyl moiety and D-glutamic acid, respectively. The title compound was selected as a promising candidate for further evaluation among several related analogues on the basis of an immunorestoration test in mice. This novel nor-MDP analogue protects mice against the immunosuppressive effect of cyclophosphamide and increases the nonspecific resistance of mice against fungal infection. It is an immunomodulator which enhances the maturation of lymphocytes B to plasma cells and increases the activity of lymphocytes B and lymphocytes T as well as that of macrophages but does not alter the number of these cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484503     DOI: 10.1021/jm970509d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy.

Authors:  Chikako Ogawa; Yuen-Joyce Liu; Koichi S Kobayashi
Journal:  Curr Bioact Compd       Date:  2011-09

2.  Chemical conjugation of muramyl dipeptide and paclitaxel to explore the combination of immunotherapy and chemotherapy for cancer.

Authors:  Xuqin Li; Junli Yu; Song Xu; Nan Wang; Hongzhen Yang; Zheng Yan; Guifang Cheng; Gang Liu
Journal:  Glycoconj J       Date:  2007-12-27       Impact factor: 2.916

Review 3.  Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Authors:  Sanja Nabergoj; Irena Mlinarič-Raščan; Žiga Jakopin
Journal:  Med Res Rev       Date:  2018-12-13       Impact factor: 12.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.